ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 2471 • 2015 ACR/ARHP Annual Meeting

    Increased Muscle Interferon-Gamma Expression Levels in Juvenile Dermatomyositis

    Gian Marco Moneta1, Adele D'Amico2, Margherita Verardo3, Denise Pires Marafon4, Luisa Bracci Laudiero5, Fabrizio De Benedetti6 and Rebecca Nicolai7, 1Department Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy, 2Department of Neuroscience,, Unit of Neuromuscular and Neurodegenrative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy, 3Department of Neuroscience, Unit of Neuromuscular and Neurodegenrative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy, 4Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 5Rheumatology Laboratory, Bambino Gesú Children Hospital, Rome, Italy, 6Pediatric Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, 7Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

    Background/Purpose : Juvenile dermatomyositis (JDM) is a rare autoimmune disorder characterized by muscle weakness, skin rashes and other systemic features. The immunopathogenesis of JDM is…
  • Abstract Number: 721 • 2015 ACR/ARHP Annual Meeting

    Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus

    Richard Furie1, M Khamashta2, L Wang3, J Drappa3, W Greth3 and G Illei3, 1Division of Rheumatology, North Shore - LIJ Health System, New York, NY, 2Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, 3MedImmune, Gaithersburg, MD

    Background/Purpose: Most randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors to ensure a balanced allocation of subgroups that might respond differently…
  • Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting

    Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women

    Yuli McCann1, Meredith Barnes1 and Grant Hughes2, 1Medicine, University of Washington, Seattle, WA, 2Medicine/Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Female sex steroids are important modulators of autoimmunity.  Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…
  • Abstract Number: 801 • 2015 ACR/ARHP Annual Meeting

    Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1

    Xuebing Feng1, Weiwei Chen2, Lihui Xiao1 and Lingyun Sun2, 1Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose: While type I interferon (IFN) has been linked to atherosclerosis progression in systemic lupus erythematosus (SLE), little is known about its regulation and intervention.…
  • Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting

    Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon

    Helena Tydén1, Christian Lood2, Birgitta Gullstrand3, Andreas Jönsen4 and Anders A. Bengtsson5, 1Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, 2Department of Clinical Sciences, Division of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, 3Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital, Lund University, Lund, Sweden, 4Department of Rheumatology, Lund University Hospital, Lund, Sweden, 5Rheumatology, Inst of Clinical sciences, Lund, Sweden

    Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
  • Abstract Number: 802 • 2015 ACR/ARHP Annual Meeting

    Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus

    Lingling Wu1, Bo Qu1, Yuting Qin1 and Nan Shen1,2, 1Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2The Center for Autoimmune Genomics and Etiology (CAGE),Cincinnati Children’s Hospital Medical Center,Cincinnati, Ohio, United States of America, Cincinnati, OH

    Background/Purpose: Type I interferon (IFN) signaling has been  a central pathogenic pathway in systemic lupus erythematosus (SLE). The application of specific inhibitors of IFN  pathway has emerged…
  • Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting

    Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial

    Xiang Guo1, L Wang2, G Illei3, P Brohawn1, Brandon Higgs1 and Wendy White1, 1Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 2MedImmune, Gaithersburg, MD, 3Clinical Development, MedImmune, LLC, Gaithersburg, MD

    Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
  • Abstract Number: 807 • 2015 ACR/ARHP Annual Meeting

    High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation

    Uma Thanarajasingam1, Mark A. Jensen2, Jessica M. Dorschner3 and Timothy B. Niewold3, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN

    Background/Purpose: IFN-alpha is a pathogenic factor in SLE.  High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with increased disease severity…
  • Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting

    Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

    Richard Furie1, JT Merrill2, VP Werth3,4, M Khamashta5, K Kalunian6, P Brohawn7, G Illei7, J Drappa7, L Wang7 and S Yoo8, 1North Shore-LIJ Health System, New York, NY, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Philadelphia V.A. Medical Center, Philidelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, 6UCSD School of Medicine, La Jolla, CA, 7MedImmune, Gaithersburg, MD, 8Regenx Bio, Rockville, MD

    Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…
  • Abstract Number: 992 • 2015 ACR/ARHP Annual Meeting

    Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus

    Laurence Morel1, Seung-Chul Choi2, Zhiwei Xu2, Elisabeth Adkins3, Byron Croker2 and Derry Roopenian3, 1Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, 2University of Florida, Gainesville, FL, 3The Jackson Laboratory, Bar Harbor, ME

    Background/Purpose: Cellular metabolism controls T cell functions, with TCR-mediated activation enhancing metabolism, and substrate utilization modulating effector functions.  Autoreactive CD4 T cells are key effectors…
  • Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting

    Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue

    Shervin Assassi1, Maureen D Mayes1, Claudia Pedroza2, Jeffrey T. Chang2, Daniel E. Furst3, Leslie J. Crofford4, Richard Nash5, Peter McSweeney5, Mary Ellen Csuka6, Ellen Goldmuntz7, Lynette Keyes-Elstein8, Paul Wallace9 and Keith Sullivan10, 1Rheumatology, University of Texas Medical School at Houston, Houston, TX, 2University of Texas Medical School at Houston, Houston, TX, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Medicine, Vanderbilt University, Nashville, TN, 5Colorado Blood Cancer Institute, Denver, CO, 6Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, 7NIAID, National Institutes of Health, Bethesda, MD, 8Rho Federal Systems, Inc., Chapel Hill, NC, 9Roswell Park, Buffalo, NY, 10Duke University, Durham, NC

    Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
  • Abstract Number: 1015 • 2015 ACR/ARHP Annual Meeting

    Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice

    Sarah Woller1, Cody Ocheltree2, Tony Yaksh1 and Maripat Corr2, 1Anesthesiology, UCSD, La Jolla, CA, 2Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA

    Background/Purpose: Male C57Bl/6 (WT) mice develop transient inflammation in response to K/BxN serum transfer and show a corresponding pain state, which persists beyond the resolution…
  • Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting

    Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus

    Naomi I Maria1, M. Javad Wahadat1, Cornelia G. van Helden-Meeuwsen1, Annette van Dijk-Hummelman2, Radboud JEM Dolhain3, Sylvia Kamphuis2 and Marjan A. Versnel1, 1Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…
  • Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting

    Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts

    Georg Pongratz1, Rainer Straub2 and Torsten Lowin3, 1Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, 2Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine I, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
  • Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting

    Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases

    Tamarah D. de Jong1, Saskia Vosslamber1, Elise Mantel1, Sander de Ridder1, John G. Wesseling1, Tineke C.T.M. van der Pouw Kraan2, Joep Killestein3, Ingrid E. Lundberg4, Jiri Vencovsky5,6, Irene E.M. Bultink7, Alexandre E. Voskuyl8, Michiel Pegtel1, Conny J. van der Laken9, Johannes W. Bijlsma8 and Cornelis L. Verweij1, 1Pathology, VU University medical center, Amsterdam, Netherlands, 2Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands, 3Neurology, VU University medical center, Amsterdam, Netherlands, 4Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 7Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, 8Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, 9Rheumatology, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology